ENDOCRINOLOGY IN THE TIME OF COVID-19 Clinical management of neuroendocrine neoplasms (NENs)

Show simple item record

dc.contributor University of Helsinki, HUS Abdominal Center en
dc.contributor.author Casey, Ruth T.
dc.contributor.author Valk, Gerlof D.
dc.contributor.author Schalin-Jäntti, Camilla
dc.contributor.author Grossman, Ashley B.
dc.contributor.author Thakker, Rajesh V.
dc.date.accessioned 2021-01-13T10:00:02Z
dc.date.available 2021-01-13T10:00:02Z
dc.date.issued 2020-08
dc.identifier.citation Casey , R T , Valk , G D , Schalin-Jäntti , C , Grossman , A B & Thakker , R V 2020 , ' ENDOCRINOLOGY IN THE TIME OF COVID-19 Clinical management of neuroendocrine neoplasms (NENs) ' , European Journal of Endocrinology , vol. 183 , no. 2 , pp. G79-G88 . https://doi.org/10.1530/EJE-20-0424 en
dc.identifier.issn 0804-4643
dc.identifier.other PURE: 145221084
dc.identifier.other PURE UUID: 024f003d-957e-42a4-a61e-842e0cade1ef
dc.identifier.other WOS: 000565546600010
dc.identifier.uri http://hdl.handle.net/10138/324471
dc.description.abstract In viral pandemics, most specifically Covid-19, many patients with neuroendocrine neoplasms (NENs), including phaeochromocytomas, paragangliomas and medullary thyroid carcinoma, may develop Covid-19 in a mild or severe form, or be concerned about the influence of viral infection relative to their anti-tumoral therapy. In general, newly presenting patients should be assessed, and patients recently receiving chemotherapy, targeted therapy or radionuclide therapy, or showing tumour growth, should be closely followed. For previously diagnosed patients, who have indolent disease, some delay in routine follow-up or treatment may not be problematic. However, patients developing acute secretory syndromes due to functional neuroendocrine neoplasms (such as of the pancreas, intestine or lung), phaeochromocytomas and paragangliomas, will require prompt treatment. Patients with life-threatening Covid-19-related symptoms should be urgently treated and long-term anti-tumoral treatments may be temporarily delayed. In patients with especially aggressive NENs, a careful judgement should be made regarding the severity of any Covid-19 illness, tumour grade, and the immunosuppressant effects of any planned chemotherapy, immunotherapy (e.g. interferon-alpha), targeted therapy or related treatment. In other cases, especially patients with completely resected NENs, or who are under surveillance for a genetic disorder, a telephone or delayed consultation may be in order, balancing the risk of a delay against that of the possible development of Covid-19. en
dc.format.extent 10
dc.language.iso eng
dc.relation.ispartof European Journal of Endocrinology
dc.rights en
dc.subject ENETS CONSENSUS GUIDELINES en
dc.subject TUMORS en
dc.subject RECEPTOR en
dc.subject 3121 General medicine, internal medicine and other clinical medicine en
dc.title ENDOCRINOLOGY IN THE TIME OF COVID-19 Clinical management of neuroendocrine neoplasms (NENs) en
dc.type Article
dc.description.version Peer reviewed
dc.identifier.doi https://doi.org/10.1530/EJE-20-0424
dc.type.uri info:eu-repo/semantics/other
dc.type.uri info:eu-repo/semantics/publishedVersion
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl

Files in this item

Total number of downloads: Loading...

Files Size Format View
_1479683X_Europ ... ocrine_neoplasms_NENs_.pdf 1.124Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record